Korbel Gregory Alan
Known title: Chief Business OfficerCIK: 0001789032
Associated companies
Transaction History
| APRE | ▲ Buy | Grant | 24,300 | $0 | 7/28/2022 | View on chart |
| APRE | ▼ Sell | Tax Withholding | 8,390 | $7K | 6/3/2022 | View on chart |
| APRE | ▼ Sell | Tax Withholding | 1,989 | $4K | 3/10/2022 | View on chart |
| APRE | ▲ Buy | Grant | 16,000 | $0 | 3/10/2022 | View on chart |
| APRE | ▼ Sell | Tax Withholding | 1,326 | $2K | 2/25/2022 | View on chart |
| APRE | ▲ Buy | Option Exercise | 27,500 | $25K | 12/1/2021 | View on chart |
| APRE | ▼ Sell | Open Market | 27,500 | $109K | 12/1/2021 | View on chart |
| APRE | ▲ Buy | Option Exercise | 27,500 | $25K | 11/1/2021 | View on chart |
| APRE | ▼ Sell | Open Market | 27,500 | $138K | 11/1/2021 | View on chart |
| APRE | ▲ Buy | Option Exercise | 27,500 | $25K | 10/1/2021 | View on chart |
| APRE | ▼ Sell | Open Market | 27,500 | $134K | 10/1/2021 | View on chart |
| APRE | ▲ Buy | Option Exercise | 27,500 | $25K | 9/20/2021 | View on chart |
| APRE | ▼ Sell | Open Market | 27,500 | $137K | 9/20/2021 | View on chart |
| APRE | ▼ Sell | Open Market | 5,460 | $27K | 9/20/2021 | View on chart |
| APRE | ▼ Sell | Tax Withholding | 1,724 | $8K | 9/10/2021 | View on chart |
| APRE | ▼ Sell | Tax Withholding | 1,149 | $5K | 8/25/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Aprea Therapeutics Announces October Conference Presentations
Aprea Therapeutics will present at several conferences in October. The company’s appearance is intended to share progress on its research and development efforts. The presentation may offer new information to investors and analysts about the company’s pipeline and strategy. The event is a routine update for the company’s stakeholders.
Aprea Therapeutics Announces October Conference Presentations. Aprea Therapeutics will present at several conferences in October. The company’s appearance is intended to share progress on its research and development efforts. The presentation may offer new information to investors and analysts about the company’s pipeline and strategy. The event is a routine update for the company’s stakeholders.